Time to Sell Mylan Amid Epipen Controversy
Post# of 105
Mylan , famously known as the maker of EpiPen, grabbed our attention in the past few weeks in a very negative way. This is because of the sudden increase in the price of EpiPens. Unbelievable, but yes with almost 500% increase since 2007, today the drug- a life-saving treatment for allergic reactions-costs almost $608. And the company fails at providing any valid reason for this jump in price.
Because of all this office of Attorney General Eric Schneiderman launched an antitrust probe of the EipPen contracts. Due to this new issue, Mylan shares are trading in red. Analysts rate this stock ‘Sell’.